SCG2

Across TCGA pan-cancer cohorts, SCG2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of SCG2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where SCG2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SCG2 is over-expressed in tumor, although a few such as COAD and PDAC show the opposite, repressed pattern.

COAD, PDAC, and LSCC are the cancer types where SCG2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SCG2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	All	−2.085	<.001	12	view →
PDAC	All	II,III,IV	−0.705	<.001	9	view →
LSCC	All	All	−0.604	.004	4	view →
LUAD	Female	All	−0.604	.006	2	view →
HNSC	Male	All	−0.478	.019	2	view →
CCRCC	All	All	−0.295	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

SCG2–COAD

Open the COAD breakdown →